Dihydroartemisinin/piperaquine (DHA-PPQ) 40/320 mg is approved for the treatment of Plasmodium falciparum uncomplicated malaria. Different recommendations are provided by WHO guidelines and drug data sheet about dosing in overweight patients. We report here a treatment failure likely caused by sub-optimal dosing of dihydroartemisinin-piperaquine in a case of uncomplicated P. falciparum malaria in a returning traveler from Burkina Faso.
To cite this article
Treatment failure due to the potential under-dosing of dihydroartemisinin-piperaquine in a patient with Plasmodium falciparum uncomplicated malaria
Infectious Diseases & Tropical Medicine 2019;
Submission date: 01 Feb 2019
Revised on: 11 Mar 2019
Accepted on: 10 May 2019
Published online: 31 May 2019